• Home
  • NEW DAY MEDICINE
  • 10 (48) 2022
  • 13 -10 (48) 2022 — Mirzaabdullakhozhieva O.U., Zufarova Sh.A. — ANALYSIS OF SERUM INTERFERONS AND IL-28B IN PREGNANT WOMEN WITH CHRONIC VIRAL HEPATITIS B

13 -10 (48) 2022 — Mirzaabdullakhozhieva O.U., Zufarova Sh.A. — ANALYSIS OF SERUM INTERFERONS AND IL-28B IN PREGNANT WOMEN WITH CHRONIC VIRAL HEPATITIS B

ANALYSIS OF SERUM INTERFERONS AND IL-28B IN PREGNANT WOMEN WITH CHRONIC VIRAL HEPATITIS B

Mirzaabdullakhozhieva O.U., Tashkent Pediatric Medical Institute, Uzbekistan

Zufarova Sh.A., Tashkent Pediatric Medical Institute, Uzbekistan

Yuldasheva O.S.Tashkent Pediatric Medical Institute, Uzbekistan

Resume

A two-fold suppression of serum IL-28 was revealed in women with hepatitis B compared with the data of practically healthy pregnant women. Thus, it was revealed that in the group of pregnant women with hepatitis B, the IL-28 value was 3.74±0.92 pg/ml, while the norm for practically healthy pregnant women was 12.8±0.75 pg/ml, which significantly differed. Thus, our studies have shown that the values of interferon gamma and IFN-lambda, which are pronounced antiviral proteins, are significantly suppressed against the background of chronic viral hepatitis B in pregnant women in the early stages of pregnancy, which can lead to pronounced suppression of cellular immunity and activation of viral replication. Research in this area will be continued in order to understand the etiopathogenesis, the features of the course of the infectious process and the prediction of the course of the disease. IFN-gamma is a powerful activator of innate immunity, therefore, the suppression of IFN-gamma and IFN-lambda in women with HCV indicates the suppression of not only antiviral immunity, but also the systemic immune response. Thus, our studies have shown that the values of interferon gamma and IFN-lambda, which are pronounced antiviral proteins, are significantly suppressed against the background of chronic viral hepatitis B in pregnant women in the early stages of pregnancy, which can lead to pronounced suppression of cellular immunity and activation of viral replication. Research in this area will be continued in order to understand the etiopathogenesis, the features of the course of the infectious process and the prediction of the course of the disease.

Keywords: interferons, immunity, antiviral effect, interferon system, antiviral immunity protection, viral hepatitis B.

First page

70

Last page

75

For citation:Mirzaabdullakhozhieva O.U., Zufarova Sh.A., Yuldasheva O.S.ANALYSIS OF SERUM INTERFERONS AND IL-28B IN PREGNANT WOMEN WITH CHRONIC VIRAL HEPATITIS B //New Day in Medicine 10(48)2022 70-75 https://clck.ru/32S96m

LIST OF REFERENCES:

  1. Artamonov A.V., Bekarev A.A., Dygai A.M., Zhdanov V.V., Kinsht D.N., Madonov P.G., Sherstoboev E Yu. Pegylated interferon lambda for oral administration, and method for producing the same. Patent 2678332 RF; Publ. 01/28/2019.
  2. Maldov D.G., Andronova V.L., Grigoryan S.S., Isaeva E.I., Balakina A.A., Terentev A.A., Ilichev A.V., Galegov G.A. The mechanism of stimforte action on herpesvirus infection. Voprosyvirusologii = Problems of Virology. 2018; 63 (5): 218–222. doi: 10.18821/0507-4088-2018-63-5-218-223
  3. Ank N., West H., Bartholdy C., Eriksson K., Thomsen A.R., Paludan S.R. Lambda interferon (IFNlambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 2006; 80(9): 4501–4509. doi:10.1128/JVI.80.9.4501-4509.2006
  4. Bandi P., Pagliaccetti N.E., Robek M.D. Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins. J. Interferon Cytokine Res. 2010; 30(3): 123–134. doi:10.1089/jir.2009.0049
  5. Baños-Lara Mdel R., Harvey L., Mendoza A., Simms D., Chouljenko V.N., Wakamatsu N., Kousoulas K.G., Guerrero-Plata A. Impact and regulation of lambda interferon response in human metapneumovirus infection. J. Virol. 2015; 89(1): 730–742. doi: 10.1128/JVI.02897-14
  6. Bartlett N.W., Buttigieg K., Kotenko S.V., Smith G.L. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J. Gen. Virol. 2005; 86(6): 1589–1596. doi: 10.1099/vir.0.80904-0
  7. Blazek K., Eames H.L., Weiss M., Byrne A.J., Perocheau D., Pease J.E., Doyle S., McCann F., Williams R.O., Udalova I.A. IFN-l resolves inflammation via suppression of neutrophil infiltration and IL1b production. J. Exp. Med. 2015; 212:845–853. doi:10.1084/jem.20140995
  8. Cui L., Yu F., Ma J., Pei H., Zuo L. Effects of DENV-2 infection on the expression of IL-29 in primary HUVECs cultured on hydrogel substrates. Chinese Journal of Microbiology and Immunology (China). 2015; 35(1):7–13. doi: 10.3760/cma.j.is sn.0254-5101.2015.01.002
  9. Dantas A.T., Gonçalves S.M., Pereira M.C., de Almeida A.R., Marques C.D., Rego M.J., Pitta Ida R., Duarte A.L., Pitta M.G. Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29). autoimmunity. 2015; 48(7): 429–433. doi: 10.3109/08916934.2015.1054028
  10. Davidson S., McCabe T.M., Crotta S., Gad H.H., Hessel E.M., Beinke S., Hartmann R., Wack A. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Mol. Med. 2016; 8(9): 1099–112. doi:10.15252/emmm.201606413
  11. Douam F., Soto Albrecht Y.E., Hrebikova G., Sadimin E., Davidson C., Kotenko S.V., Ploss A. Type III interferon-mediated signaling is critical for controlling live attenuated yellow fever virus infection in vivo. MBio. 2017; 8(4): e00819-17. doi: 10.1128/mBio.00819-17.
  12. Espinosa V., Dutta O., McElrath C., Du P., Chang Y.J., Cicciarelli B., Pitler A., ​​Whitehead I., Obar J.J., Durbin J.E., Kotenko S.V., Rivera A. Type III interferon is a critical regulator of innate antifungal immunity. sci. Immunol. 2017; 2 (16): eaan5357. doi:10.1126/sciimmunol.aan53
  13. Flisiak R., Shiffman M., Arenas J., Cheinquer H., Nikitin I., Dong Y., Rana K., Srinivasan S. A randomized study of peginterferon lambda-1a compared to peginterferon alfa-2a in combination with ribavirin and telaprevir in patients with genotype-1 chronic hepatitis C. PLoS One. 2016; 11(10): e0164563. doi: 10.1371/journal.pone.0164563.
  14. Ha Y.J., Choi Y.S., Kang E.H., Chung J.H., Cha S., Song Y.W., Lee Y.J. Increased expression of interferon-λ in minor salivary glands of patients with primary Sjögren’s syndrome and its synergic effect with interferon-α on salivary gland epithelial cells. Clin. Exp. Rheumatol. 2018; 36 (Suppl. 112, 3): 31–40.

file

download